Member Info for K3VMC

86KB

“ Fantastic results out, what an opportunity at these levels before getting deals.”

What results? All I see in this RNS are opinions and assertions.

No data.

My 100k buy at 7.4p being delayed

As always happens. Bought at 2.8p.

Peter Shea should be the kiss of death.

They skillfully avoided mentioning his involvement in Ben’s Creek, which also went belly up and certain directors are currently in the dock in the US, charged with fraud.

Peter Shea presided over Daniel Stewart, which crashed and burned, fuelled by my piles of cash.

I was tempted to sell out of BEN when Peter Shea joined the company, but was deceived by statements made by Adam Wilson. That was a bad mistake.

Happily, I’m not involved here. And won’t be under any circumstances and at any price.

Better and better results here.

Happy to hold and wait for profits.

9.5p. That’s the price AC get for his £500k. Only seems fair.

They will use their profit for the next, very deeply discounted, placing.

We will be over 10p sooner than you think.

From the CEO’s statement. NB the last paragraph.

"Our company delivered a very strong performance in 2024 with Total Revenue and Core EPS up 21% and 19% respectively. We also delivered nine positive high value Phase III studies in the year, which coupled with increasing demand for our medicines in all key regions, will help sustain our growth momentum into 2025.

This year marks the beginning of an unprecedented, catalyst-rich period for our company, an important step on our Ambition 2030 journey to deliver $80 billion Total Revenue by the end of the decade. In 2025 alone, we anticipate the first Phase III data for seven new medicines, along with several important new indication opportunities for our existing medicines.

We are also investing in and making significant progress with transformative technologies that have the potential to drive our growth well beyond 2030, many of which have now entered pivotal trials."

“ 8: What factors support the likelihood of Zenith winning in disputes two and three?

Andrea Cattaneo (CEO) Zenith Energy Ltd: The fact that they used the same method for making crimes in case 1, 2 and 3. All copy-paste, without fantasy. These breaches have been sentenced in full in ICC1. Arbitration courts # 2 & #3, similarly composed of high caliber arbitrators, will most likely issue a similar sentence according to our assessment.

9: Hypothetically, if Zenith wins one of the two remaining disputes—or both—how does the company plan to allocate these funds?

Andrea Cattaneo (CEO) Zenith Energy Ltd: I wish to reassure investors of the bonafide of our intentions. We shall keep in mind as well the victory in ICC 1 which we have in our hands. As soon as we receive the money in full from the sequestration process/es under the Award received for ICC1, the Board may consider, under the advice of our securities lawyers and investment bankers, ways to distribute an initial payout to our shareholders.”

Rock on!

Jarri888

“NFX and IMM show it doesn't take much to shift micro cap bios”

I missed NFX, but did well from IMM. Having lost considerable sums investing in lying, bent ceos in mining and oil and gas, the evidence of many peer-reviewed scientific papers gives me confidence in the potential medical benefits of SFX01.

The percentage shareholding of IIs and LTHs gives me confidence in the commercial possibilities.

£3.8m is a steal and 10-20x a real possibility.

I’ve been accumulating EVE / TCF for years.

Formerlyeasyp

“ According to the above 37.21% of TCF is owned by institutional investors.”

Don’t forget long term PI holder Robert Kight, with 8.1%.

I believe it also doesn’t include First Equity increasing their holding from 5.42% to 6.01%

14.29% up.

Offered 0.99p for 100k.

Back up to placing price.

What’s cooking? Smells good!

MMs needed two buy in that stock, to settle the stock they sold at higher levels.

Now we can move up.

That should definitely put legs on AGL.

Moab

“ Has been around as digitalis since ~1770. Anyone can make it. Nothing, precisely nothing, in it for GSK.”

Your point is?

It’s a new use for an old thing. If it helps prevent metastasis, then it’s a very valuable new use for an old thing. And do they need Parsortix to identify clusters?

I can’t say I have any worries over GSK.

To$$er

Has anyone spotted the typo in that paper yet?

Blindingly simple, but only made possible by the technology designed and patented by AGL.

How many times have we heard of friends who were declared “free” from cancer, but passed from metastases within five years? My wife was one of them. She passed in 2002, but for cancer sufferers NOW, there is a mechanism to test their blood at regular intervals, to check if there are CTCs and take early measures if the disease is spreading.

If this service was available I would be paying for it as often as was practically possible.

It’s a clear breakthrough in cancer therapy.

6.13p

Probably not leaky. Not very likely.

Up we go.